CD4 Effector T Cell Expansion to Identify Objective Responses to the CD40 Agonist Mitazalimab in Combination with Modified FOLFIRINOX (mffx) As First-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma (mpdac) in the OPTIMIZE-1 Study.